---
figid: PMC8524770__10.1177_15353702211019697-fig4
figtitle: Sex hormones in lung cancer
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC8524770
filename: 10.1177_15353702211019697-fig4.jpg
figlink: /pmc/articles/PMC8524770/figure/fig4-15353702211019697/
number: F4
caption: 'Progesterone/progesterone receptor signaling in lung cancer. The growth
  factor receptor signaling is stimulated by its ligands (e.g. EGF, IFG-1, HRG), resulting
  in the activation of MAPK-related pathways and the subsequent stimulation of both
  (1) the ligand independent receptor activation and (2) the AKT/mTOR pathway, which
  increases and suppresses PR expression, respectively. In addition, estrogen and
  progesterone promote VEGF in lung cancer. (A color version of this figure is available
  in the online journal.)AKT: AKT Serine/Threonine Kinase 1; E: estrogen; EGF: epidermal
  growth factor; ERβ: estrogen receptor β; GFR: growth factor receptor; HRG: histidine
  rich glycoprotein; IGF-1: insulin-like growth factor 1; MAPK: mitogen-activated
  protein kinases; mTOR: mechanistic target of rapamycin; P: progesterone; PI3K: phosphoinositide-3
  kinase; PR: progesterone receptor; PRE: progesterone response elements; VEGF: vascular
  endothelial growth factor.'
papertitle: Role of sex hormones in lung cancer.
reftext: Nathalie Fuentes, et al. Exp Biol Med (Maywood). 2021 Oct;246(19):2098-2110.
year: '2021'
doi: 10.1177/15353702211019697
journal_title: Experimental Biology and Medicine
journal_nlm_ta: Exp Biol Med (Maywood)
publisher_name: SAGE Publications
keywords: Lung | cancer | sex differences | sex hormones | carcinogenesis | estrogen
  receptors
automl_pathway: 0.9591429
figid_alias: PMC8524770__F4
figtype: Figure
redirect_from: /figures/PMC8524770__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8524770__10.1177_15353702211019697-fig4.html
  '@type': Dataset
  description: 'Progesterone/progesterone receptor signaling in lung cancer. The growth
    factor receptor signaling is stimulated by its ligands (e.g. EGF, IFG-1, HRG),
    resulting in the activation of MAPK-related pathways and the subsequent stimulation
    of both (1) the ligand independent receptor activation and (2) the AKT/mTOR pathway,
    which increases and suppresses PR expression, respectively. In addition, estrogen
    and progesterone promote VEGF in lung cancer. (A color version of this figure
    is available in the online journal.)AKT: AKT Serine/Threonine Kinase 1; E: estrogen;
    EGF: epidermal growth factor; ERβ: estrogen receptor β; GFR: growth factor receptor;
    HRG: histidine rich glycoprotein; IGF-1: insulin-like growth factor 1; MAPK: mitogen-activated
    protein kinases; mTOR: mechanistic target of rapamycin; P: progesterone; PI3K:
    phosphoinositide-3 kinase; PR: progesterone receptor; PRE: progesterone response
    elements; VEGF: vascular endothelial growth factor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - pre
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - Egfr
  - hrg
  - pr
  - prp
  - gfr
  - nac
  - MKP-4
  - p38b
  - rl
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - Mtor
  - Tor
  - ESR2
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - EGF
  - IGF1
  - HRG
  - NRG1
  - SLC48A1
  - C4BPA
  - PRNP
  - PRDX2
  - ABCB6
  - CARD14
  - RAPGEF5
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
---
